Cingulate Inc (CING) — Titan Protect Analysis

CING

Cingulate Inc

Healthcare · ·

$4.49

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$61M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.87

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-225.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$22.50

+401% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Cingulate Inc

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In

https://www.cingulate.com

Country: United States Employees: 14 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.560

Good returns relative to risk taken

Kelly Fraction

0.0756

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

-0.313

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-25.4%

Historical annualised return based on price data

Max Drawdown

-81.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.81

Very low correlation to market moves

52W High

$11.89

62% below the year high

52W Low

$3.16

42% above the year low

Avg Volume

661,587

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.33

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

39.38

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-11,919,704

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-27,909,322

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$55.00

Target Median

$22.50

Target Low

$8.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
9 Apr2026	Scott Peters	Democrat	buy	50K–100K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go